David Emanuelson | People | Arnold & Porter

David Emanuelson is a member of the firm’s Antitrust/Competition practice. Prior to joining Arnold & Porter, David held multiple in-house antitrust leadership positions for over a decade, as Chief M&A Regulatory Counsel and Associate General Counsel for Intel Corporation and Head of Antitrust Americas for Novartis Corporation.

David advises clients on merger analysis, complex private antitrust litigation, government investigations, and antitrust compliance. His practice focuses on antitrust issues in the technology and life sciences industries. David currently serves as co-chair of the firm’s Semiconductor Working Group and has extensive experience advising clients on antitrust issues involving cutting-edge technologies such as artificial intelligence, semiconductor manufacturing, autonomous driving, 5G networking, and biotechnology.

David also has deep experience in M&A regulatory issues involving the intersection of antitrust and national security, including CFIUS, ex-U.S. foreign direct investment, and U.S. export control issues. He is one of the few antitrust lawyers outside of China with significant experience directly interacting with the Chinese regulatory authority (SAMR).

David began his career in private practice and spent over a decade representing clients in complex antitrust litigation and government investigations in the microprocessor, chemicals, telecommunications, airline, television, dairy, and automotive refinishing paint industries.

David maintains an active pro bono practice.

Focus Areas

Experience

Pharmacosmos A/S in its US$405 million acquisition of G1 Therapeutics Inc.
Cognizant in its US$1.3 billion acquisition of Belcan.
Intel in its acquisition of Silicon Mobility, a fabless silicon and software company that specializes in software-defined vehicle system-on-chips for intelligent electric vehicle energy management.
IT services company in its acquisition of a firm that provides business solutions to the Department of Defense and other government agencies.

David’s in-house experience includes:

For Intel

Led global regulatory team securing worldwide regulatory approvals for its US$9 billion sale of its NAND memory business to SK hynix.*
Led global regulatory team in its proposed US$5.4 billion acquisition of Tower Semiconductor.*
Advised corporate venture capital arm (Intel Capital) on regulatory issues and antitrust compliance for minority investments.*
Handled multiple government investigations involving merger review, abuse of dominance, and standard setting practices in the technology industry, appearing in front of the Federal Trade Commission, U.S. Department of Justice, European Commission, SAMR, and numerous other international authorities.*
Successfully litigated complex commercial litigation as Associate General Counsel in Intel’s Commercial Litigation group.*

For Novartis

Led Americas regulatory teams securing merger clearance for multiple multi-billion dollar transactions from 2013-2017, including Novartis’s three-part asset swap with GSK involving oncology, vaccines, and consumer health.*
Led team that successfully litigated in re Gleevec sham litigation case related to Hatch-Waxman Act patent settlement.*
Developed and oversaw antitrust compliance processes for Hart-Scott-Rodino filings, Hatch-Waxman Act patent settlement practices, and lifecycle management strategies.*

*Reflects experience at previous employer.